Pottumarthi
Prasad1, Wei Li1, Thomas Schnitzer2, Nitya
Krishnan3, Deborah Burstein3
1NorthShore University HealthSystem,
Evanston, IL, United States; 2Feinberg School of Medicine,
Northwestern University, Chicago, IL, United States; 3Radiology,
Beth Israel Deaconess Medical Center, Boston, MA, United States
Treatment
of osteoarthritis remains to be symptom modification, although the concept of
disease modification is currently evolving. Hylan G-F 20 has been shown to
demonstrate disease modifying effects, even though it is currently approved
for symptom modification. We have performed preliminary evaluation to see if
dGEMRIC can detect changes in patients treated with Hylan G-F 20 in a small
number of subjects. While we observed little change, we believe this may be
due to the relatively advanced disease status. This is in general agreement with
other published human trials using joint space width as an outcome measure.